Multiply-substituted protease variants

US6815193B2 · kind B2 · utility

Assignee

• GENENCOR INTERNATIONAL, INC. · US

Inventors

• Ayrookaran J. Poulose · Belmont, US
• Volker Schellenberger · Palo Alto, US
• James T. Kellis, Jr. · Redwood City, US
• Christian Paech · Santa Rosa, US
• Joanne Nadherny · San Francisco, US
• Donald P. Naki · San Francisco, US
• Katherine D. Collier · Redwood City, US
• Robert M. Caldwell · Belmont, US
• Andre Baeck · Bonheiden, BE

Key dates

• Filing date: Nov 2, 2001
• Grant date: Nov 9, 2004
• Expiry date: Jan 28, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2800/86
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel protease variants derived from the DNA sequences of naturally-occurring or recombinant non-human proteases are disclosed. The variant proteases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant protease to generate the substitution of a plurality of amino acid residues in the amino acid sequence of a precursor protease. Such variant proteases have properties which are different from those of the precursor protease, such as altered wash performance. The substituted amino acid residue corresponds to position 103 in combination with one or more of the following substitutions at residue positions corresponding to positions 1, 3, 4, 8, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 24, 27, 33, 37, 38, 42, 43, 48, 55, 57, 58, 61, 62, 68, 72, 75, 76, 77, 78, 79, 86, 87, 89, 97, 98, 99, 101, 102, 104, 106, 107, 109, 111, 114, 116, 117, 119, 121, 123, 126, 128, 130, 131, 133, 134, 137, 140, 141, 142, 146, 147, 158, 159, 160, 166, 167, 170, 173, 174, 177, 181, 182, 183, 184, 185, 188, 192, 194, 198, 203, 204, 205, 206, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 222, 224, 227, 228, 230, 232, 236, 237, 238, …